Webb1 mars 2024 · Recro (NASD: REPH) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New … Webb15 mars 2024 · The corporate mailing address for Mr. Enloe, Jr. and other Recro Pharma executives is 490 LAPP ROAD, MALVERN PA, 19355. Recro Pharma can also be reached via phone at (770) 534-8239 and via email at [email protected]. Has J. David Enloe, Jr. been buying or selling shares of Recro Pharma?
Recro Pharma, Inc. completed the acquisition of Cornell University ...
WebbSelected as President and CEO to re-launch company (formerly Recro Pharma) as a free-standing, publicly traded CDMO after its spinout from … Webb5 sep. 2024 · MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care ... notice taken crossword
Recro Announces Name Change to Societal CDMO™ to Reflect …
Webb21 mars 2024 · SAN DIEGO and GAINESVILLE, Ga., March 21, 2024 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it … WebbThe RECOPHARMA Project was born with the purpose of designing, developing, validating and demonstrating an effective treatment to recover the Recalcitrant Cytostatic Drugs … Webb12 aug. 2024 · On August 13, 2024, Recro Pharma, Inc. (the "Company" or "Recro") entered into a Unit Purchase Agreement (the "Purchase Agreement") by and among the Company, IriSys, LLC, a California limited liability company ("IriSys"), IriSys, Inc., a California corporation ("IriSys Parent"), Continent Pharmaceuticals U.S., Inc., a Delaware … notice takepayments.com